>
Advanz Pharma logo

ADVZ - Advanz Pharma Share Price

C$6.2 -0.2  -3.1%

Last Trade - 27/03/20

Sector
Healthcare
Size
Mid Cap
Market Cap £730.3m
Enterprise Value £1.56bn
Revenue £372.9m
Position in Universe th / 2708
Bullish
Bearish
Unlock ADVZ Revenue
Momentum
Relative Strength (%)
1m +0.33%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
394.2 816.2 626.2 537 508.3 525.6 546 +5.9%
-64.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, AdvanzPharma Corp Ltd revenues increased 5% to $136.1M. Net lossincreased 75% to $15.2M. Revenues reflect ADVANZ PHARMAInternational segment increase of 14% to $110.4M, UnitedStates segment increase from $1.7M to $25.7M. Higher netloss reflects ADVANZ PHARMA North America segment incomedecrease of 54% to $6.4M, Corporate segment loss increaseof 76% to $11.1M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADVZ Revenue Unlock ADVZ Revenue

Net Income

ADVZ Net Income Unlock ADVZ Revenue

Normalised EPS

ADVZ Normalised EPS Unlock ADVZ Revenue

PE Ratio Range

ADVZ PE Ratio Range Unlock ADVZ Revenue

Dividend Yield Range

ADVZ Dividend Yield Range Unlock ADVZ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ADVZ EPS Forecasts Unlock ADVZ Revenue
Profile Summary

ADVANZ PHARMA Corp. Limited is a United Kingdom-based pharmaceutical company. It is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. The Company is focused on investing in product portfolio to optimize healthcare treatment. Its therapy areas include endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders and intensive care medicines. The Company optimizes healthcare treatment through product acquisitions, in-licensing opportunities, product development and alliances worldwide. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products and operates facilities in various locations, including Sydney, Australia; Mumbai, India; Dublin, Ireland; St. Helier, Jersey; Helsingborg, Sweden, and Chicago, United States.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: n/a
No. of Employees: 429
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Toronto Stock Exchange
Shares in Issue 48,913,490
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADVZ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADVZ
Upcoming Events for ADVZ
Frequently Asked Questions for Advanz Pharma
What is the Advanz Pharma share price?

As of 27/03/20, shares in Advanz Pharma are trading at C$6.2, giving the company a market capitalisation of £730.3m. This share price information is delayed by 15 minutes.

How has the Advanz Pharma share price performed this year?

Shares in Advanz Pharma are currently trading at C$6.2 and the price has moved by -70.8% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Advanz Pharma price has moved by -77.66% over the past year.

What are the analyst and broker recommendations for Advanz Pharma?

Of the analysts with advisory recommendations for Advanz Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Advanz Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Advanz Pharma next release its financial results?

Advanz Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Advanz Pharma dividend yield?

Advanz Pharma does not currently pay a dividend.

Does Advanz Pharma pay a dividend?

Advanz Pharma does not currently pay a dividend.

When does Advanz Pharma next pay dividends?

Advanz Pharma does not currently pay a dividend.

How do I buy Advanz Pharma shares?

To buy shares in Advanz Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Advanz Pharma?

Shares in Advanz Pharma are currently trading at C$6.2, giving the company a market capitalisation of £730.3m.

Where are Advanz Pharma shares listed? Where are Advanz Pharma shares listed?

Here are the trading details for Advanz Pharma:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: ADVZ
What kind of share is Advanz Pharma?

We were not able to load our ranking data for Advanz Pharma

Is there a Advanz Pharma share price forecast 2021?

We were not able to load any forecast data for Advanz Pharma.

How can I tell whether the Advanz Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanz Pharma. Over the past six months, the relative strength of its shares against the market has been -66.73%. At the current price of C$6.2, shares in Advanz Pharma are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Advanz Pharma PE Ratio?

We were not able to find PE ratio data for Advanz Pharma.

Who are the key directors of Advanz Pharma?

We were unable to find the directors for Advanz Pharma.

Who are the major shareholders of Advanz Pharma?

Here are the top five shareholders of Advanz Pharma based on the size of their shareholding:

Capital Fixed Income Investors Investment Advisor
Percentage owned: 5.88% (2.88m shares)
American Funds American High-Income Trust Mutual Fund
Percentage owned: 5.48% (2.68m shares)
JP Morgan Asset Management Investment Advisor
Percentage owned: 4.17% (2.04m shares)
Barings (U.K.) Limited Investment Advisor
Percentage owned: 3.28% (1.61m shares)
Barings European Loan Fund Mutual Fund
Percentage owned: 3.28% (1.61m shares)
Similar to ADVZ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.